tbuckley/cabot-search huggingface dataset:
SURG-05. EXPERIENCE PROFILING OF FLUORESCENCE-GUIDED SURGERY FOR GLIOMAS
Authors: So Young Ji, Chae Eun Lee, Tamrin Chowdhury, Jin Wook Kim, Chul-Kee Park
Journal: Neuro-Oncology (2019)

Abstract Numerous studies reported a usefulness of 5-ALA fluorescence-guided surgery (FGS) in high grade gliomas. However, fluorescence pattern and intensity is variable among gliomas. In this study, we report our extensive experiences of FGS in various gliomas focusing on epidemiological data of fluorescence pattern. A total of 827 histologically proven glioma patients out of 900 brain tumor patients who had undergone FGS using 5-ALA during the period of 8.5 years between July 2010 and January 2019 were analyzed. Indication for FGS in glioma surgery harbored any evidence of possible high-grade foci at presumed gliomas in preoperative magnetic resonance images (MRI). Among the 827 gliomas, the number of cases corresponding to 2016 World Health Organization (WHO) grade IV, III, II, and I are 528 (58.7%), 193 (21.4%), 87 (9.7%) and 19 (2.1%), respectively. In terms of fluorescence rate, grade IV gliomas showed positive fluorescence in 95.4% of cases including strong intensity in 85.6%. Grade III gliomas showed fluorescence in about half of cases (55.0%), while 45.0% of cases did not show any fluorescence. Anaplastic oligodendroglioma had more positive rate (63.9%) than anaplastic astrocytoma (46.2%). Both grade II and I gliomas still showed positive fluorescence in about one-fourths of cases (24.1% and 26.3%, respectively). Among them ependymoma and pilocytic astrocytoma were fluorescence-prone tumors. This epidemiological data of 5-ALA fluorescence in various grades of gliomas provides fundamental reference to clinical application of FGS using 5-ALA in glioma surgery.
A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)
Authors: Yuankai Shi, Lin Gui, Junning Cao, Huilai Zhang, Jun Zhu, Dongmei Ji, Qian Fan, Yuqin Song, Weina Shen, Guiying Bai, Ming-Zhe Han, Shiyu Jiang
Journal: Blood (2019)
High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma
Authors: Aleš Obr, Pavel Klener, Eva Kriegova, Zuzana Zemanova, Helena Urbankova, Andrea Jirkuvova, Anna Petrackova, Barbora Cudova, Lenka Sedlarikova, VIT K Prochazka, Tomas Papajik, Marek Trneny
Journal: Blood (2019)
Gpibα Engagement Induces Activation of Human Platelet TF and Association with Constitutively Platelet Surface-Bound FVIIa
Authors: Olga Panes, M. Francisca Becerra, Roger Valle, Claudia G Sáez, Patricia Hidalgo, Jaime Pereira, Jennifer Royce, Wolfram Ruf, Diego Mezzano
Journal: Blood (2019)
Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study
Authors: Svetlana Trestman, Chezi Ganzel, Shai Levi, Moshe E. Gatt, Noa Lavi, Iuliana Vaxman, Ory Rouvio, Hila Magen, Netanel A Horowitz, Merav Leiba, Tamar Tadmor, Katrin Herzog Tzarfati, Celia Surio, Shay Yeganeh, Nagib Deli, Irit Avivi, Cohen Yael
Journal: Blood (2019)
Hmga2 Functions As an Oncogene upon the Deletion of Tet2 and Promotes the Pathogenesis of Myelodysplastic Syndrome
Authors: Jie Bai, Sho Kubota, Takako Yokomizo, Akinori Kanai, Yuqi Sun, Mihoko Iimori, Hironori Harada, Naomi Nakagata, Atsushi Iwama, Goro Sashida
Journal: Blood (2019)
A Signature of Differentially Expressed Micrornas in Lymphoblastoid Cells from Shwachman-Diamond Syndrome Patients Indicates Possible Molecular Targets for Mirna Therapeutics
Authors: Jessica Gasparello, Chiara Papi, Giulia Breveglieri, Elisabetta D'Aversa, Valentino Bezzerri, Giovanna D'Amico, Marco Cipolli, Roberto Gambari, Monica Borgatti, Alessia Finotti
Journal: Blood (2019)
Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies
Authors: Anja Feldmann, Stefanie Koristka, Claudia Arndt, Liliana Raquel Loureiro, Ralf Bergmann, Nicole Berndt, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, Václav Hořejší, Michael Bachmann
Journal: Blood (2019)
Cross Sectional Survey of Priapism and Sexual Dysfunction in 353 Men with Sickle Cell Disease
Authors: Ibrahim Musa Idris, Jamil Aliyu Galadanci, Akib Abba, Sharfuddeen Abbas Mashi, Anele Uzoma, Kemberlee R Bonnet, David G Schlundt, Nafiu Hussain, Arthur Burnett, Michael R. DeBaun
Journal: Blood (2019)
Probing the Impedance of a Biological Tissue with PEDOT:PSS‐Coated Metal Electrodes: Effect of Electrode Size on Sensing Efficiency
Authors: Dimitrios A. Koutsouras, Leona V. Lingstedt, Katharina Lieberth, Jonas Reinholz, Volker Mailänder, Paul W. M. Blom, Paschalis Gkoupidenis
Journal: Advanced Healthcare Materials (2019)

Electrodes coated with poly(3,4-ethylenedioxythiophene):polystyrene sulfonate (PEDOT:PSS) have been employed to measure the integrity of cellular barriers. However, a systematic experimental study of the correlation between tissue integrity and impedance of the sensing device has not yet been conducted. Using impedance spectroscopy, how the impedance ratio of the biological tissue to the recording device affects the recording ability of the latter is investigated. PEDOT:PSS-coated electrodes of various dimensions are employed and the effect of their size to their sensing efficiency is examined. The biotic/abiotic ensemble is modeled with a simple equivalent circuit and an analytical expression of the total impedance as a function of frequency is extracted. The results reveal a critical impedance ratio of the biological tissue to the sensor which allows for efficient sensing of the tissue integrity. This work provides the ground rules for improved impedance-based biosensors with optimized sensitivity.
Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes
Authors: Kanagaraju Ponnusamy, Maria-Myrsini Tzioni, Murshida Begum, Mark E Robinson, Valentina S Caputo, Alexia Katsarou, Nikolaos Trasanidis, Xiaolin Xiao, Ioannis V. Kostopoulos, Deena Iskander, Irene Roberts, Pritesh Trivedi, Holger W Auner, Kikkeri Naresh, Aristeidis Chaidos, Anastasios Karadimitris
Journal: Blood (2019)
Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
Authors: Christian M. Schuerch, Darci J. Phillips, Salil S. Bhate, Graham L. Barlow, Steven P Fling, Nirasha Ramchurren, Robert Pierce, Martin A Cheever, Michael S. Khodadoust, Youn H. Kim, Garry P. Nolan
Journal: Blood (2019)
Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
Authors: Thomas G. Knight, Myra Robinson, Jing Ai, Brittany K Ragon, Rhonda Davis, Cindy Shiflett, Erica Ruston, Hailey Glover, Jigar Trivedi, Belinda R Avalos, Jonathan M. Gerber, James T Symanowski, Edward A Copelan, Michael R. Grunwald
Journal: Blood (2019)
Mutant ASXL1 Disrupts Paraspeckle Formation through Aberrant Interaction with Nono in Hematopoietic Cells
Authors: Yamamoto Keita, Susumu Goyama, Shuhei Asada, Takeshi Fujino, Tomofusa Fukuyama, Yosuke Tanaka, Ayana Kon, Yasuhito Nannya, Seishi Ogawa, Reina Onoguchi, Nobuyoshi Akimitsu, Toshio Kitamura
Journal: Blood (2019)
ST2 and Rg3a As a Biomarker for Predicting of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Hakan Goker, Elifcan Aladag, Yahya Buyukasik, Nelson J. Chao, Umit Akman, Haluk Demiroglu
Journal: Blood (2019)
A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors
Authors: Hanna A. Knaus, Hubert Hackl, Amanda Blackford, Sofia Berglund, Raul Montiel-Esparza, Joshua F Zeidner, Ivana Gojo, Leo Luznik
Journal: Blood (2019)
NCMP-03. AN UNUSUAL CASE OF NEUROBLASTOMA ASSOCIATED OMS: HIGH RISK DISEASE REQUIRING IMMUNOTHERAPY
Authors: Jessica Stiefel, Yasmin Khakoo, Ellen Basu, Rina Meyer, Gurcharanjeet Kaur
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Opsoclonus-myoclonus-ataxia syndrome (OMS) is a rare paraneoplastic syndrome (PNS) typically associated with low-risk pediatric neuroblastoma (NB). Overall survival is excellent but patients are at risk for long-term neurologic sequelae. As with many PNS, the etiology of NB-associated OMS is thought to be immune mediated and patients are managed with immunosuppressive therapy. The use of other immunotherapy such as checkpoint inhibitors for advanced stage cancers has been associated with sporadic reports of the development of PNS. We report a case of a child with NB-associated OMS who received anti-GD2 antibody immunotherapy for advanced relapsed NB without exacerbation of OMS. While the mechanism of action of anti-GD2 is unique, this case demonstrates that further study is required to understand which patients are at risk for PNS development/flare during therapy for advanced stage cancers. CASE: Our patient presented at 16 months of age with acute onset of tremors, irritability and ataxia and was diagnosed with OMS; at that time, evaluation revealed intermediate risk stage 4 neuroblastoma which was treated with 4 cycles of chemotherapy with complete response. His OMS was managed initially with high dose dexamethasone, followed by monthly IVIG, ACTH and rituximab with improvement in neurologic symptoms. The patient developed NB relapse (stage 4) 18 months after completion of initial chemotherapy and received chemotherapy and anti-GD2 antibody immunotherapy. Through this second course of therapy he continued to wean his immunosuppressive anti-OMS therapy without flare of his neurologic symptoms. DISCUSSION We present an unusual case of a child with NB-associated OMS whose OMS symptoms did not flare despite the use of immunotherapy to treat relapsed stage 4 disease. CONCLUSION While immunosuppression is used to treat OMS and other paraneoplastic syndromes, the use of immunotherapy to treat the underlying malignancy may be tolerated. Further study is needed.
Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes
Authors: Sheyu Li, Imola Nemeth, Louise Donnelly, Simona Hapca, Kaixin Zhou, Ewan R. Pearson
Journal: Diabetes Care (2019)

To investigate the association between visit-to-visit HbA1c variability and cardiovascular events and microvascular complications in patients with newly diagnosed type 2 diabetes.This retrospective cohort study analyzed patients from Tayside and Fife in the Scottish Care Information-Diabetes Collaboration (SCI-DC) who were observable from the diagnosis of diabetes and had at least five HbA1c measurements before the outcomes were evaluated. We used the previously reported HbA1c variability score (HVS), calculated as the percentage of the number of changes in HbA1c >0.5% (5.5 mmol/mol) among all HbA1c measurements within an individual. The association between HVS and 10 outcomes was assessed using Cox proportional hazards models.We included 13,111-19,883 patients in the analyses of each outcome. The patients with HVS >60% were associated with elevated risks of all outcomes compared with the lowest quintile (for example, HVS >80 to ≤100 vs. HVS ≥0 to ≤20, hazard ratio 2.38 [95% CI 1.61-3.53] for major adverse cardiovascular events, 2.4 [1.72-3.33] for all-cause mortality, 2.4 [1.13-5.11] for atherosclerotic cardiovascular death, 2.63 [1.81-3.84] for coronary artery disease, 2.04 [1.12-3.73] for ischemic stroke, 3.23 [1.76-5.93] for heart failure, 7.4 [3.84-14.27] for diabetic retinopathy, 3.07 [2.23-4.22] for diabetic peripheral neuropathy, 5.24 [2.61-10.49] for diabetic foot ulcer, and 3.49 [2.47-4.95] for new-onset chronic kidney disease). Four sensitivity analyses, including adjustment for time-weighted average HbA1c, confirmed the robustness of the results.Our study shows that higher HbA1c variability is associated with increased risks of all-cause mortality, cardiovascular events, and microvascular complications of diabetes independently of high HbA1c.
Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18
Authors: Agnieszka Malecka, Jan Delabie, Ingunn Ostlie, Anne Tierens, Ulla Randen, Sigbjorn Berentsen, Geir Erland Tjønnfjord, Gunhild Trøen
Journal: Blood (2019)
Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression
Authors: Ignacio Iñigo-Marco, Marta M. Alonso
Journal: Journal of Clinical Investigation (2019)

Tumor-induced immunosuppression is a common obstacle for cancer treatment. Adrenergic signaling triggered by chronic stress participates in the creation of an immunosuppressive microenvironment by promoting myeloid-derived suppressor cell (MDSC) proliferation and activation. In this issue of the JCI, Mohammadpour et al. elegantly delve into the mechanisms underlying MDSC contribution to tumor development. They used in vitro and in vivo mouse models to demonstrate that chronic stress results in MDSC accumulation, survival, and immune-inhibitory activity. Of therapeutic relevance, the authors showed that propranolol, a commonly prescribed β-blocker, can reduce MDSC immunosuppression and enhance the effect of other cancer therapies.
Wound Closure with Adhesive Tape
Authors: P. J. W. Rowell
Journal: BMJ (1964)

MEDILlHdue to neuromuscular block of respiratory muscles, since they could have completely recovered.With the existing knowledge, could I suggest another explanation of the events in the case reported by Dr. Ross and his colleagues ?The presence of curare-like block on E.M.G. could be due to recurarization as a result of 180 mg. of gallamine, used in a patient with poor circulation, poor renal function, and a very low serum calcium level.The respiratory inadequacy at the end of operation in spite of 2.5 mg. of neostigmine could be attributed to the existence of metabolic acidosis, maintained and accentuated by superadded respiratory acidosis with or without partial recurarization.Oral neomycin has a distinct advantage of its own in the prevention of complications after elective surgery on the colon ; therefore, before surgeons can accept the suggestion that "neomycin should be kept to a minimum" more convincing proof is required.-Iam, etc.,
The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma
Authors: Yurie Nagai, Naoya Mimura, Ola Rizq, Yusuke Isshiki, Motohiko Oshima, Mohamed Rizk, Atsunori Saraya, Shuhei Koide, Yaeko Nakajima-Takagi, Makiko Miyota, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Shio Mitsukawa, Yusuke Takeda, Chikako Ohwada, Masahiro Takeuchi, Tohru Iseki, Chiaki Nakaseko, Josephine Sheedy, Marla Weetall, Atsushi Iwama, Emiko Sakaida
Journal: Blood (2019)
Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning
Authors: Adithya Chennamadhavuni, Kalyan Nadiminti, Lindsay Dozeman, Umar Farooq, Yogesh Jethava, Sarah Mott, Margarida Magalhaes Silverman
Journal: Blood (2019)
Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas
Authors: Jonathan Pan, Sushil Ghimire, Tingting Zhan, Onder Alpdogan, Andrew E. Chapman, Matthew Carabasi, Ubaldo Martinez-Outschoorn, Lewis J. Rose, Michael Ramirez, John L Wagner, Barbara Pro, Mark A. Weiss, Neal Flomenberg, Pierluigi Porcu, Joanne Filicko-O'Hara, Sameh Gaballa
Journal: Blood (2019)
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients
Authors: Elizabeth A. Griffiths, Hagop M. Kantarjian, Casey L. O'Connell, Karen W.L. Yee, Wendy Stock, Naval G. Daver, Elias Jabbour, Ellen K. Ritchie, Jean-Pierre Issa, Katherine J. Walsh, David A. Rizzieri, Scott D. Lunin, Xiang Yao Su, Mohammad Azab, Gail J. Roboz
Journal: Blood (2019)
Transition Continuity Promotes Long-Term Retention in Adult Care Among Young Adults with Sickle Cell Disease
Authors: Anjelica C. Saulsberry, Kristen Howell, Joacy Mathias, Jerlym S. Porter, Jason R. Hodges, Kenneth I. Ataga, Sheila Anderson, Vikki Nolan, Jane S. Hankins
Journal: Blood (2019)
POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
Authors: Andrew K McMillan, Matthew J Matasar, Juan-Manuel Sancho, Andreas Viardot, Juana Hernandez, Thomas Perretti, Corinne Haioun
Journal: Blood (2019)
Early Hematopoietic Progenitors of Dkc1 Hypomorphic Mutant Mice Display Decreased Proliferation Rate and an Impaired Control of Serine/Arginine-Rich Splicing Factor 4 (Srsf4) Translation
Authors: Antonio R Lucena-Araujo, Bárbara A Santana-Lemos, Carol H Thome, Germano A Ferreira, Davide Ruggero, Vitor Marcel Faça, Eduardo M Rego
Journal: Blood (2014)
Impact of Different Doses of Fludarabine in Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation
Authors: Kodai Kuriyama, Shigeo Fuji, Noriko Doki, Yuta Katayama, Souichi Shiratori, Yukiyasu Ozawa, Takashi Ashida, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Masao Ogata
Journal: Blood (2019)
Problems of an Ageing Population
Authors: J. H. Sheldon
Journal: BMJ (1960)

Marginal zone B cells (MZB) participate in the early immune response to several pathogens. In this study, we show that in μMT mice infected with <i>Leishmania donovani</i>, CD8 T cells displayed a greater cytotoxic potential and generated more effector memory cells compared with infected wild type mice. The frequency of parasite-specific, IFN-γ<sup>+</sup> CD4 T cells was also increased in μMT mice. B cells were able to capture parasites, which was associated with upregulation of surface IgM and MyD88-dependent IL-10 production. Moreover, MZB presented parasite Ags to CD4 T cells in vitro. Depletion of MZB also enhanced T cell responses and led to a decrease in the parasite burden but did not alter the generation of effector memory T cells. Thus, MZB appear to suppress protective T cell responses during the early stages of <i>L. donovani</i> infection.
Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes
Authors: Fabio Efficace, Pasquale Niscola, Francesco Cottone, Gianluca Gaidano, Amelie Anota, Franck Bonnetain, Giovanni Caocci, Luana Fianchi, Massimo Breccia, Reinhard Stauder, Uwe Platzbecker, Giuseppe A Palumbo, Mario Luppi, Rosangela Invernizzi, Micaela Bergamaschi, Marilena Fedele, Anna Angela Di Tucci, Huiyong Zhang, Marco Vignetti, Franco Mandelli
Journal: Blood (2016)
Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma
Authors: Niels Weinhold, Jing Xu, Martina Fröhlich, Alexandra M Poos, Lukas John, Carsten Müller-Tidow, Sandra Sauer, Stefanie Huhn, Dirk Hose, Anja Seckinger, Kari Hemminki, Benedikt Brors, Hartmut Goldschmidt, Nicola Giesen, Marc S Raab
Journal: Blood (2019)
Development of a Severity Score System for Thalassemia Syndromes
Authors: Angela Vitrano, Antonella Meloni, Walter Addario Pollina, Mehran Karimi, Amal El-Beshlawy, Mahmoud Hajipour, Vito Di Marco, Saqib Hussain Ansari, Aldo Filosa, Paolo Ricchi, Adriana Ceci, Shahina Daar, Sylvia Titi Titi Singer, J F Borgio, Alessia Pepe, Salvatore Scondotto, Gabriella Dardanoni, Rosario Di Maggio, Massimiliano Sacco, Elliott P. Vichinsky, Aurelio Maggio
Journal: Blood (2019)
A New TALe to Tell?
Authors: Frank White, David Norman
Journal: Cell Host & Microbe (2019)

In this issue of Cell Host & Microbe, Wu et al. (2019) propose that a bacterial type III effector modifies the host milieu specifically to inhibit competing pathogens with little effect on the inciting pathogen populations. The work raises awareness to examine effectors for niche modification and has implications for the microbial community structure.
BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome
Authors: Cynthia J. Sieben, Karthik B. Jeganathan, Grace G. Nelson, Ines Sturmlechner, Cheng Zhang, Willemijn H. van Deursen, Bjorn Bakker, Floris Foijer, Hu Li, Darren J. Baker, Jan M. van Deursen
Journal: Journal of Clinical Investigation (2019)

Mosaic-variegated aneuploidy (MVA) syndrome is a rare childhood disorder characterized by biallelic BUBR1, CEP57, or TRIP13 aberrations; increased chromosome missegregation; and a broad spectrum of clinical features, including various cancers, congenital defects, and progeroid pathologies. To investigate the mechanisms underlying this disorder and its phenotypic heterogeneity, we mimicked the BUBR1L1012P mutation in mice (BubR1L1002P) and combined it with 2 other MVA variants, BUBR1X753 and BUBR1H, generating a truncated protein and low amounts of wild-type protein, respectively. Whereas BubR1X753/L1002P and BubR1H/X753 mice died prematurely, BubR1H/L1002P mice were viable and exhibited many MVA features, including cancer predisposition and various progeroid phenotypes, such as short lifespan, dwarfism, lipodystrophy, sarcopenia, and low cardiac stress tolerance. Strikingly, although these mice had a reduction in total BUBR1 and spectrum of MVA phenotypes similar to that of BubR1H/H mice, several progeroid pathologies were attenuated in severity, which in skeletal muscle coincided with reduced senescence-associated secretory phenotype complexity. Additionally, mice carrying monoallelic BubR1 mutations were prone to select MVA-related pathologies later in life, with predisposition to sarcopenia correlating with mTORC1 hyperactivity. Together, these data demonstrate that BUBR1 allelic effects beyond protein level and aneuploidy contribute to disease heterogeneity in both MVA patients and heterozygous carriers of MVA mutations.
Absolute Lymphocyte Count at 1st Remission Is Prognostic Factor for Disease Free and Overall Survival for Acute Myeloid Leukemia Under 60: Analysis of AML1 GOELAMS Trial
Authors: Bruno Lioure, Christian Recher, Patrice Chevallier, Arnaud Pigneux, Francis Witz, Norbert Vey, Nathalie Fegueux, Claude-Eric Bulabois, Sylvie Daliphard, Fabrice Larosa, Martine Escoffre-Barbe, Eric Jourdan, Olivier Tournilhac, Martine Delain, Denis Caillot, Mario Ojeda, Edouard Randriamalala, Roselyne Delepine, Francois Dreyfus, Norbert Ifrah
Journal: Blood (2008)